TR200401264T4 - CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları. - Google Patents

CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.

Info

Publication number
TR200401264T4
TR200401264T4 TR2004/01264T TR200401264T TR200401264T4 TR 200401264 T4 TR200401264 T4 TR 200401264T4 TR 2004/01264 T TR2004/01264 T TR 2004/01264T TR 200401264 T TR200401264 T TR 200401264T TR 200401264 T4 TR200401264 T4 TR 200401264T4
Authority
TR
Turkey
Prior art keywords
obesity
treatment
combination
pharmaceutical compositions
receptor
Prior art date
Application number
TR2004/01264T
Other languages
English (en)
Inventor
Piot-Grosjean Odile
Picaut Philippe
Petitet Fran�ois
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200401264(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of TR200401264T4 publication Critical patent/TR200401264T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu bulus bir CB1 reseptör anatagonisti ve sibütramin birlesimi, bunlari içeren farmasötik bilesimler ve obezite tedavisinde kullanimlarina iliskindir.
TR2004/01264T 2000-10-04 2001-10-01 CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları. TR200401264T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Publications (1)

Publication Number Publication Date
TR200401264T4 true TR200401264T4 (tr) 2004-07-21

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01264T TR200401264T4 (tr) 2000-10-04 2001-10-01 CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.

Country Status (29)

Country Link
EP (1) EP1328269B2 (tr)
JP (1) JP4221221B2 (tr)
KR (1) KR20030036885A (tr)
CN (1) CN100409845C (tr)
AT (1) ATE267595T1 (tr)
AU (2) AU2001293936B2 (tr)
BG (1) BG107739A (tr)
BR (1) BR0114410A (tr)
CA (1) CA2424934A1 (tr)
DE (1) DE60103556T3 (tr)
DK (1) DK1328269T5 (tr)
EA (1) EA005924B1 (tr)
EE (1) EE200300121A (tr)
ES (1) ES2217191T5 (tr)
FR (1) FR2814678B1 (tr)
HR (1) HRP20030249A2 (tr)
HU (1) HUP0302044A3 (tr)
IL (1) IL155236A0 (tr)
MX (1) MXPA03002845A (tr)
NO (1) NO20031521L (tr)
NZ (1) NZ524904A (tr)
PL (1) PL362833A1 (tr)
PT (1) PT1328269E (tr)
SI (1) SI1328269T2 (tr)
SK (1) SK4032003A3 (tr)
TR (1) TR200401264T4 (tr)
WO (1) WO2002028346A2 (tr)
YU (1) YU26103A (tr)
ZA (1) ZA200303015B (tr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
MXPA05000962A (es) 2002-07-29 2005-05-16 Hoffmann La Roche Nuevos benzodioxoles.
US7135488B2 (en) 2003-01-02 2006-11-14 Hoffmann-La Roche Inc. Pyrrolyl-thiazole derivatives
MXPA05007114A (es) 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
AU2004252109B2 (en) 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
CA2528785A1 (en) 2003-06-20 2005-01-06 Matthias Heinrich Nettekoven 2-amidobenzothiazoles as cb1 receptor inverse agonists
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
WO2005020992A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
CN100509808C (zh) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
CN100572375C (zh) 2004-01-28 2009-12-23 霍夫曼-拉罗奇有限公司 螺－苯并间二氧杂环戊烯及其作为cb1拮抗剂的应用
ES2324720T3 (es) 2004-05-10 2009-08-13 F. Hoffmann-La Roche Ag Pirrol o imidazol amidas para tratar la obesidad.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
AU2005298986A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
BRPI0517653A (pt) 2004-11-09 2008-10-14 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
JP2009528999A (ja) * 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド Ｃｂ１アンタゴニストおよび逆アゴニスト
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
JP5030114B2 (ja) * 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AR069700A1 (es) * 2007-12-18 2010-02-10 Sanofi Aventis Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
AU723879C (en) † 1996-10-31 2003-11-06 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (fr) † 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
WO1999006110A1 (en) * 1997-07-29 1999-02-11 Silicon Genesis Corporation Cluster tool method and apparatus using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
IL141769A0 (en) † 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation

Also Published As

Publication number Publication date
SK4032003A3 (en) 2003-09-11
ES2217191T5 (es) 2009-02-16
AU2001293936B2 (en) 2007-01-25
HUP0302044A3 (en) 2005-05-30
EA005924B1 (ru) 2005-08-25
FR2814678B1 (fr) 2002-12-20
ES2217191T3 (es) 2004-11-01
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
DE60103556T3 (de) 2009-04-09
JP2004512279A (ja) 2004-04-22
YU26103A (sh) 2006-08-17
ATE267595T1 (de) 2004-06-15
NO20031521L (no) 2003-04-24
EP1328269B2 (fr) 2008-07-30
HUP0302044A2 (hu) 2003-11-28
DK1328269T3 (da) 2004-09-20
PT1328269E (pt) 2004-08-31
DK1328269T5 (da) 2009-03-16
BR0114410A (pt) 2004-02-17
BG107739A (bg) 2004-01-30
SI1328269T2 (sl) 2008-12-31
KR20030036885A (ko) 2003-05-09
EP1328269A2 (fr) 2003-07-23
EE200300121A (et) 2005-04-15
DK1328269T4 (da) 2008-11-24
JP4221221B2 (ja) 2009-02-12
EP1328269B1 (fr) 2004-05-26
WO2002028346A3 (fr) 2002-08-29
FR2814678A1 (fr) 2002-04-05
CA2424934A1 (fr) 2002-04-11
EA200300441A1 (ru) 2003-08-28
IL155236A0 (en) 2003-11-23
HRP20030249A2 (en) 2005-02-28
CN1473040A (zh) 2004-02-04
DE60103556D1 (de) 2004-07-01
ZA200303015B (en) 2004-02-26
CN100409845C (zh) 2008-08-13
AU9393601A (en) 2002-04-15
WO2002028346A2 (fr) 2002-04-11
PL362833A1 (en) 2004-11-02
DE60103556T2 (de) 2005-06-30
MXPA03002845A (es) 2004-09-10
NZ524904A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
EE200300121A (et) CB1 retseptori antagonisti ja sibutramiini kombinatsioon, neid sisaldav farmatseutiline kompositsioon ja kasutamine lihavuse raviks
TR199802423T2 (tr) Konsantre antikor terkibi.
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
TR200200768T2 (tr) Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
YU68002A (sh) Modifikovani faktor viii
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
DE69812159D1 (de) Derivate des adamantan
DE69905170T2 (de) Thiazolopyrimidinderivate
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
ATE330017T1 (de) Kallikrein gen
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
TR200002896T2 (tr) Kalsilitik Bileşimler
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
TR200103396T2 (tr) Anti-fas antikoru içeren farmasötik terkipler.
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
TR200003323T2 (tr) Geniş-tesir sahalı mantar önleyiciler olarak suda eriyebilir azoller
TR199801452T2 (tr) Jinekolojik rahatsizliklarin tedavisinde kullanilan LHRH analoglari ve antiöstrojenlerden mütesekkil farmakolojik kombine madde.